Cipher Pharmaceuticals (CPH) Q1 2025 earnings summary

Executive summary

• Q1 2025 net revenue rose 105% year-over-year to $12.0M, driven by the Natroba acquisition and strong Canadian sales, including Epuris.

• Natroba generated $6.7M in revenue, aligning with expectations and benefiting from seasonality and Medicaid wins in Illinois.

• Net income was $2.6M, down from $4.9M year-over-year, reflecting higher operating expenses post-acquisition.

• Adjusted EBITDA increased 73% to $6.2M, highlighting improved core operating performance.

• Specialty pharma company strategy includes acquiring complementary products, maximizing cash flow, and out-licensing internationally.

Financial highlights

• Total net revenue was $12M in Q1 2025, up 105% year-over-year, mainly due to Natroba.

• Licensing revenue fell 72% to $700K, impacted by lower shipments and increased generic competition.

• Canadian product portfolio revenue rose 41% to $4.6M; on constant currency, up 50%.

• Gross margin on product revenue increased to 74% (87% for Natroba excluding non-cash adjustments).

• Adjusted EBITDA for Q1 2025 was $6.2M, up 73% from Q1 2024.

Outlook and guidance

• Expectation of higher Natroba revenues in Q2 and Q3 due to seasonality, with anticipated high single to low double-digit quarterly growth.

• Management expects current cash, credit facility, and operating cash flows to support the business plan for 2025 and beyond.

• Ongoing pursuit of accretive acquisitions and in-licensing opportunities, with a disciplined approach.

• Focus remains on leveraging U.S. infrastructure for future product launches and potential Canadian expansion.

• Ongoing investments in product launches, R&D, and regulatory approvals are anticipated.